Prof Richard S Kaplan
Prof Richard S Kaplan
MRC Clinical Trials Unit at University College London
Verified email at
Cited by
Cited by
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ...
European journal of cancer 45 (2), 228-247, 2009
New guidelines to evaluate the response to treatment in solid tumors
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, ...
Journal of the National Cancer Institute 92 (3), 205-216, 2000
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
HU Ahmed, AES Bosaily, LC Brown, R Gabe, R Kaplan, MK Parmar, ...
The Lancet 389 (10071), 815-822, 2017
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ...
The Lancet 377 (9783), 2103-2114, 2011
Participation of patients 65 years of age or older in cancer clinical trials
JH Lewis, ML Kilgore, DP Goldman, EL Trimble, R Kaplan, MJ Montello, ...
Journal of clinical oncology 21 (7), 1383-1389, 2003
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
BF Hankey, EJ Feuer, LX Clegg, RB Hayes, JM Legler, PC Prorok, ...
Journal of the National Cancer Institute 91 (12), 1017-1024, 1999
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ...
Clinical Cancer Research 20 (20), 5322-5330, 2014
Brain and other central nervous system cancers: recent trends in incidence and mortality
JM Legler, LAG Ries, MA Smith, JL Warren, EF Heineman, RS Kaplan, ...
Journal of the National Cancer Institute 91 (16), 1382-1390, 1999
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
HA Fine, WD Figg, K Jaeckle, PY Wen, AP Kyritsis, JS Loeffler, VA Levin, ...
Journal of Clinical Oncology 18 (4), 708-708, 2000
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials
WB Sateren, EL Trimble, J Abrams, O Brawley, N Breen, L Ford, ...
Journal of clinical oncology 20 (8), 2109-2117, 2002
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant …
EA Chiocca, KM Abbed, S Tatter, DN Louis, FH Hochberg, F Barker, ...
Molecular Therapy 10 (5), 958-966, 2004
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
PY Wen, WKA Yung, KR Lamborn, PL Dahia, Y Wang, B Peng, LE Abrey, ...
Clinical Cancer Research 12 (16), 4899-4907, 2006
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results
FF Lang, JM Bruner, GN Fuller, K Aldape, MD Prados, S Chang, ...
Journal of Clinical Oncology 21 (13), 2508-2518, 2003
Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999
DG Bostwick, DJ Grignon, MEH Hammond, MB Amin, M Cohen, ...
Archives of pathology & laboratory medicine 124 (7), 995-1000, 2000
The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis
JE Olson, CA Janney, RD Rao, JR Cerhan, PJ Kurtin, D Schiff, RS Kaplan, ...
Cancer 95 (7), 1504-1510, 2002
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
Clinical trial designs for cytostatic agents: are new approaches needed?
EL Korn, SG Arbuck, JM Pluda, R Simon, RS Kaplan, MC Christian
Journal of Clinical Oncology 19 (1), 265-272, 2001
Prognostic indicators of colon tumors. The gastrointestinal tumor study group experience
SM Steinberg, JS Barkin, RS Kaplan, DM Stablein
Cancer 57 (9), 1866-1870, 1986
The system can't perform the operation now. Try again later.
Articles 1–20